Pharmacodynamics and pharmacokinetics of remazolam benzenesulfonate in critically ill patients

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100050374

Enrollment

Unknown

Registered

2021-08-26

Start date

2021-09-01

Completion date

Unknown

Last updated

2022-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intensive care unit (ICU) sedation

Interventions

Observation group:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Informed of the purpose and content of the study and signed the consent; 2. Aged 18 to 65 years; 3. ASA classification was in grade I-III; 4. Mechanical ventilation time > 48 h.

Exclusion criteria

Exclusion criteria: 1. Decompensation of vital organs (liver: child grade C; renal AKI grade > 2; GCS score < 12); 2. Patients allergic to remazolam besylate; 3. Benzodiazepine sedatives and opioid analgesics were used for a long time before enrollment; 4. A history of mental illness.

Design outcomes

Primary

Measure	Time frame
Blood pressure;Hypotension;Bradycardia;Hypoxemia;Ramsay sedation scores (RASS score);	—

Secondary

Measure	Time frame
Nausea and vomiting;Acute Physiology and Chronic Health Evaluation (APACHE) III score;Electrocardiogram (ECG);	—

Countries

China

Contacts

Public ContactYuan Yuan

Gansu Provincial Hospital

lanzhouyy@163.com+86 18919961203

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026